Filtered By:
Therapy: Statin Therapy

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 407 results found since Jan 2013.

Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research

Assessing cardiovascular disease: looking beyond cholesterol
Purpose of review The low-density lipoprotein (LDL)-cholesterol level is a weak predictor of developing cardiovascular (CV) disease and can only explain a small proportion of CV risk. It is not used to determine CV risk on either the atherosclerotic cardiovascular disease (ASCVD) calculator in the United States, or the Qrisk3 in the UK. A study in JAMA in 2022 suggested that ‘the absolute benefits of statins are modest and may not be strongly mediated through the degree of LDL reduction’. Perhaps it is time to look beyond cholesterol to a different causal model – the ‘thrombogenic’ model of ASCVD. Recen...
Source: Current Opinion in Endocrinology, Diabetes and Obesity - September 8, 2022 Category: Endocrinology Tags: OBESITY AND NUTRITION: Edited by Eric Westman Source Type: research

Treatment delay and outcomes of ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention during the COVID-19 era in South Korea
CONCLUSION: Reperfusion after STEMI treatment during the COVID-19 period was delayed; therefore, efforts should be made to improve on reperfusion.PMID:35811367 | PMC:PMC9271717 | DOI:10.3904/kjim.2022.077
Source: The Korean Journal of Internal Medicine - July 11, 2022 Category: Internal Medicine Authors: Seok Oh Myung Ho Jeong Kyung Hoon Cho Min Chul Kim Doo Sun Sim Young Joon Hong Ju Han Kim Youngkeun Ahn Source Type: research